OS Therapies (OSTX) Notes Payables (2023 - 2026)

OS Therapies' (OSTX) quarterly Notes Payables came in at $1.3 million in Q1 2026, up 437.18% on a QoQ basis from $250000.0 in Q2 2024.

OS Therapies (OSTX) Notes Payables (2023 - 2026) Analysis & Trends

OS Therapies (OSTX) has 3 years of Notes Payables data on file, last reported at $1.3 million in Q1 2026.

Quarterly Notes Payables changed N/A year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (changed N/A YoY) and the FY2023 annual result came in at $2.0 million, changed N/A from the prior year.
Notes Payables advanced to $1.3 million in Q1 2026, from $250000.0 in the prior quarter.
In the past five years, Notes Payables ranged from a high of $2.0 million in Q4 2023 to a low of $100000.0 in Q1 2024.
A 3-year average of $929816.2 and a median of $796471.0 in 2024 frame the typical range for Notes Payables.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.82 Bn	131.97 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.69 Bn	78.70 Bn	3.93 Bn
3	Argenx Se	65.23 Bn	60.05 Bn	1.37 Bn
4	Moderna	60.16 Bn	55.02 Bn	52.00 Mn
5	BeOne Medicines	42.16 Bn	37.07 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.86 Bn	28.55 Bn	992.69 Mn
7	BioNTech SE	28.24 Bn	9.85 Bn	668.28 Mn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-
10	OS Therapies	19.56 Mn	19.56 Mn	-

Download Data